Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
bmj, 2020•bmj.com
Objective To investigate the effectiveness of using convalescent plasma to treat moderate
coronavirus disease 2019 (covid-19) in adults in India. Design Open label, parallel arm,
phase II, multicentre, randomised controlled trial. Setting 39 public and private hospitals
across India. Participants 464 adults (≥ 18 years) admitted to hospital (screened 22 April to
14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial
blood/fraction of inspired oxygen (PaO 2/FiO 2) ratio between 200 mm Hg and 300 mm Hg …
coronavirus disease 2019 (covid-19) in adults in India. Design Open label, parallel arm,
phase II, multicentre, randomised controlled trial. Setting 39 public and private hospitals
across India. Participants 464 adults (≥ 18 years) admitted to hospital (screened 22 April to
14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial
blood/fraction of inspired oxygen (PaO 2/FiO 2) ratio between 200 mm Hg and 300 mm Hg …
Objective
To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India.
Design
Open label, parallel arm, phase II, multicentre, randomised controlled trial.
Setting
39 public and private hospitals across India.
Participants
464 adults (≥18 years) admitted to hospital (screened 22 April to 14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen saturation 93% or less on room air): 235 were assigned to convalescent plasma with best standard of care (intervention arm) and 229 to best standard of care only (control arm).
Interventions
Participants in the intervention arm received two doses of 200 mL convalescent plasma, transfused 24 hours apart. The presence and levels of neutralising antibodies were not measured a priori; stored samples were assayed at the end of the study.
Main outcome measure
Composite of progression to severe disease (PaO2/FiO2 <100 mm Hg) or all cause mortality at 28 days post-enrolment.
Results
Progression to severe disease or all cause mortality at 28 days after enrolment occurred in 44 (19%) participants in the intervention arm and 41 (18%) in the control arm (risk difference 0.008 (95% confidence interval −0.062 to 0.078); risk ratio 1.04, 95% confidence interval 0.71 to 1.54).
Conclusion
Convalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality. This trial has high generalisability and approximates convalescent plasma use in real life settings with limited laboratory capacity. A priori measurement of neutralising antibody titres in donors and participants might further clarify the role of convalescent plasma in the management of covid-19.
Trial registration
Clinical Trial Registry of India CTRI/2020/04/024775.
bmj.com